GLP-1 Before Surgery or Endoscopy: Coordinating With an Online Prescriber

If you take a GLP-1 prescribed through telehealth and have a colonoscopy, endoscopy or surgery on the calendar, do not decide on your own whether to skip a dose. Current multi-society guidance says most patients can keep taking their GLP-1 before elective procedures, but some higher-risk patients need a plan, and that plan should be agreed by your procedure team, your anesthesia team and your prescriber together. Your job is to make sure all three actually have the same information.

What the labels say about anesthesia and sedation

GLP-1 medicines slow how fast your stomach empties. That is part of how they reduce appetite, and it is also why anesthesiologists care: food left in the stomach during sedation can be inhaled into the lungs, which is called pulmonary aspiration.

The prescribing information for the major products now carries a specific warning. The Wegovy label (revised June 2026) describes "rare postmarketing reports of pulmonary aspiration" in patients on GLP-1 receptor agonists who had residual stomach contents during elective procedures under general anesthesia or deep sedation. The Zepbound label (revised August 2026) adds that this happened despite reported adherence to preoperative fasting.

Just as important is what the labels do not say. They state that available data are insufficient to recommend ways to reduce this risk, including whether changing fasting instructions or temporarily stopping the drug would help. The labels do not give you a hold schedule. What they do give is one instruction for the patient side:

Instruct patients to inform healthcare providers prior to any planned surgeries or procedures.

Source: current FDA prescribing information for each product, as posted by Novo Nordisk and Eli Lilly, as of October 2026.

The warning applies to the daily pills as well as the weekly injections. If you take Foundayo or the Wegovy pill, the same disclosure rule applies.

What the 2024 multi-society guidance changed

In 2023, the American Society of Anesthesiologists recommended holding weekly injectable GLP-1s for one week and oral agents for one day before surgery, according to Becker's ASC coverage of the update. A review in the AGA's GI & Hepatology News (January 2026 issue) notes that this early advice rested on expert opinion with limited evidence.

On October 29, 2024, five groups issued joint guidance: the American Society of Anesthesiologists, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons. The ASA's announcement opens with the headline finding: most patients should continue taking their GLP-1 before elective surgery. The AGA's summary says the same applies to GI endoscopy.

The guidance then lists factors that raise risk:

1. The escalation phase. Early treatment, typically the first four to eight weeks, carries higher risk, per the ASA release, and the guidance suggests deferring elective surgery until escalation is over and GI side effects settle.
2. Higher doses. These tend to bring more GI side effects.
3. Active GI symptoms. Nausea, vomiting, abdominal pain or constipation are signs the stomach may be emptying slowly.
4. Other conditions that slow stomach emptying, such as Parkinson's disease.

For patients at higher risk, the tools listed include a liquid-only diet for 24 hours before the procedure, adjusting the anesthesia plan, point-of-care ultrasound to look at stomach contents right before the procedure and, in rare cases, delaying the procedure. The guidance also asks teams to weigh the downsides of stopping the drug, including blood sugar effects for people with diabetes.

The evidence is still thin. The AGA review describes one multicenter study of roughly 800 patients in which rates of retained stomach contents differed significantly between patients who did and did not follow the earlier hold advice (12.7% vs. 4.4%), with no significant difference in aborted procedures or unplanned intubations (GI & Hepatology News). That uncertainty is why individual judgment, not a blanket rule, is the current standard.

Who decides, when your prescriber is online

The guidance frames this as a joint decision among the procedural, anesthesia and prescribing teams. In a hospital system those people can read the same chart. With a telehealth GLP-1, they usually cannot. Here is how the roles typically split:

1. The anesthesia team owns the aspiration risk on the day. They decide fasting rules, whether to scan your stomach, and whether to proceed.
2. The surgeon or endoscopist owns the procedure itself, including bowel prep instructions for a colonoscopy and whether to reschedule.
3. Your telehealth prescriber owns the medication plan: whether a pause is reasonable for you, how to restart, and whether your dose should change afterward.

None of these people should be guessing. If the procedure team says "stop your shot a week before" and your prescriber has not heard about the procedure, that is a coordination gap you can close with two messages.

What to send each side

To the procedure and anesthesia team

Many pre-op questionnaires ask about "blood thinners and diabetes medicines" and may not prompt for a weight-loss drug. Volunteer it. Send or bring:

1. The exact product name (for example Zepbound, Wegovy, compounded semaglutide, Foundayo) and whether it is weekly or daily.
2. Your current dose, and the date you last increased it.
3. Your usual injection day and the date of your last dose.
4. Any current GI symptoms: nausea, vomiting, bloating, reflux, constipation.
5. Your telehealth prescriber's name and how to reach them (portal, fax or a phone line if one exists).

To your telehealth prescriber

Send this through the platform's messaging as soon as the procedure is booked, not the week before:

1. Procedure type, date and whether it uses general anesthesia or deep sedation.
2. Any instructions the procedure team gave you about your GLP-1, word for word.
3. Your current dose and where you are in titration.
4. A direct question: "Do you agree with this plan, and how should I restart afterward?"

A decision table you can work through

Source: multi-society guidance as summarized by the ASA and AGA; product labels.

Two hypothetical scenarios

These are illustrations, not real patients.

Hypothetical A: You have been on the same tirzepatide dose for five months with no stomach symptoms, and a routine colonoscopy is booked. Under the 2024 guidance, you sound like the "most patients" group. Still, you tell the GI office your product, dose and last injection date, and you message your telehealth prescriber so your chart reflects the procedure. The GI office may still give you a modified diet the day before.

Hypothetical B: You stepped up to a new semaglutide dose two weeks ago, feel nauseated most mornings, and have a knee arthroscopy in ten days. You fall into two of the higher-risk categories at once. This is the case where the anesthesia team and your prescriber need to talk, directly or through you, about timing, a possible pause, and how to restart without repeating the hardest part of titration.

Restarting afterward by async message

If your dose was paused, restarting is a medication decision for your prescriber. The labels' missed-dose rules give the framework they will likely use:

Source: section 2 of the Wegovy, Zepbound and Foundayo prescribing information.

Why the step-down rules exist: the slow dose escalation is there to reduce nausea and vomiting. After a gap, going straight back to a high dose can bring those effects back, which matters even more while you are recovering from a procedure. A short message helps your prescriber decide quickly:

1. Date of your last dose before the procedure.
2. Date of the procedure, and any complications or new medicines (such as opioid pain relievers, which can also slow the gut).
3. How you are eating and drinking now.
4. Any nausea, vomiting, constipation or abdominal pain.
5. "Should I restart at my previous dose or a lower one, and on what day?"

If you are on a refill schedule, ask whether the pause changes your next shipment, so you do not end up with a dose you were told not to use.

Where this guide stops

This page explains labels, guidance and logistics. It cannot tell you whether your procedure should go ahead, whether to hold a dose, or what dose to restart on. Those calls belong to the clinicians who know your history.

If you cannot reach your telehealth prescriber before the procedure, tell the procedure team that. A procedure team that knows the prescriber is unreachable can plan around it. One that assumes the prescriber agreed cannot.

Sources

1. American Society of Anesthesiologists: New multi-society clinical practice guidance on GLP-1s (October 29, 2024)
2. American Gastroenterological Association: Most patients can continue GLP-1 anti-obesity drugs before surgery
3. Becker's ASC Review: ASA no longer advises holding GLP-1 patients pre-op (October 31, 2024)
4. GI & Hepatology News (AGA): GLP-1 receptor agonist use in GI endoscopy, a review of current evidence and guidelines (January 2026)
5. Wegovy prescribing information, Novo Nordisk (revised June 2026)
6. Ozempic prescribing information, Novo Nordisk (revised May 2026)
7. Zepbound prescribing information, Eli Lilly (revised August 2026)
8. Mounjaro prescribing information, Eli Lilly (revised August 2026)
9. Foundayo prescribing information, Eli Lilly (revised July 2026)

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.